Rituxan and Pregnancy: Essential Guidance for Expecting Mothers

Understanding Rituxan (Rituximab) and Pregnancy

For individuals managing chronic autoimmune conditions or certain cancers, medications like Rituxan (rituximab) are often a cornerstone of treatment. Rituxan is a powerful biologic drug that targets CD20-positive B-cells, a type of white blood cell involved in various diseases. While highly effective, the decision to continue or adjust Rituxan treatment during pregnancy presents a complex challenge for both patients and their healthcare providers. This comprehensive guide aims to shed light on the considerations, risks, and management strategies surrounding Rituxan use during pregnancy, empowering expectant mothers with vital information to make informed decisions in consultation with their medical team.

What is Rituxan (Rituximab)?

Rituxan, also known by its generic name rituximab, is a monoclonal antibody. It works by binding to the CD20 protein found on the surface of B-cells, leading to their destruction. This action helps to reduce inflammation and suppress the immune system in autoimmune diseases, or to eliminate cancerous B-cells in certain lymphomas and leukemias.

• Conditions Treated: Rituxan is approved to treat several conditions, including:
  • Rheumatoid Arthritis (RA)
  • Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) – types of vasculitis
  • Non-Hodgkin Lymphoma (NHL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Pemphigus Vulgaris (PV)
• How it’s Administered: Rituxan is typically given as an intravenous (IV) infusion in a hospital or clinic setting.

Rituxan's Impact on Pregnancy: Key Considerations

The primary concern with any medication during pregnancy is its potential effect on the developing fetus. Rituxan is classified as a Category C drug under the older FDA pregnancy classification system, meaning animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans. More recent classification systems provide a more nuanced risk assessment, focusing on a summary of risks, clinical considerations, and data.

Placental Transfer and Fetal Exposure

Rituxan is an immunoglobulin G (IgG) antibody. IgG antibodies are known to cross the placenta, especially during the second and third trimesters. This means that if a pregnant individual receives Rituxan, the medication can reach the fetus and potentially affect its developing immune system.

• Timing Matters: The extent of placental transfer increases as pregnancy progresses. Exposure during the first trimester might be lower, but by the third trimester, significant amounts of Rituxan can cross the placenta.

Potential Risks to the Fetus and Infant

The main concern with fetal exposure to rituximab is its effect on fetal B-cells. Since Rituxan targets CD20-positive B-cells, it can lead to B-cell depletion in the fetus.

• Fetal B-cell Depletion: Studies and case reports have shown that infants born to mothers exposed to Rituxan during pregnancy often have depleted or absent B-cells at birth. This effect is usually temporary, with B-cell counts typically recovering within 6 to 12 months after birth.
• Hypogammaglobulinemia: B-cells are crucial for producing antibodies (immunoglobulins) that fight infections. While the fetus primarily receives maternal antibodies for protection, persistent B-cell depletion in the infant could potentially lead to temporary hypogammaglobulinemia (low levels of immunoglobulins), making the infant more susceptible to infections.
• Increased Risk of Infection in Infants: While direct evidence of increased infection rates in infants with temporary B-cell depletion is not consistently strong, the theoretical risk exists. Healthcare providers usually recommend delaying live vaccines in these infants until their B-cell counts normalize.
• Other Potential Effects: Some case reports have noted other transient effects, such as reversible neutropenia (low white blood cell count) in newborns. However, serious long-term adverse effects directly attributable to fetal rituximab exposure appear to be rare.

Planning Pregnancy While on Rituxan

For individuals of childbearing potential on Rituxan, careful planning is crucial when considering pregnancy. Open and honest communication with your healthcare team is paramount.

Pre-conception Counseling

Before attempting to conceive, it is highly recommended to have a detailed discussion with your rheumatologist, oncologist, or other prescribing specialist, as well as an obstetrician experienced in high-risk pregnancies.

• Disease Activity: It’s generally advised to achieve stable disease remission before conception. Active disease during pregnancy can pose greater risks to both mother and fetus than medication exposure.
• Medication Review: Your doctor will review your current treatment regimen, including Rituxan, and discuss the risks and benefits of continuing, stopping, or switching medications.
• Timing of Last Dose: Rituxan has a relatively long half-life. If discontinuing Rituxan, your doctor might recommend a washout period (e.g., 6-12 months) before conception to minimize fetal exposure, depending on your condition and disease activity.
• Contraception: Effective contraception should be used during Rituxan treatment and for a period after the last dose, as advised by your doctor, if pregnancy is not desired.

Managing Rituxan During Pregnancy

The decision to continue Rituxan during pregnancy is highly individualized and depends on several factors, including the severity of the underlying condition, the trimester of pregnancy, and the potential risks versus benefits.

Weighing Risks vs. Benefits

For some conditions, particularly severe autoimmune diseases or aggressive cancers, stopping Rituxan could lead to a flare-up of the disease, which might pose a greater risk to the mother and fetus than continued medication use. Your healthcare team will help you weigh these complex factors.